Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor.

Hitomi NakatsukasaMasaya TakahashiMasahito ShibanoYusuke IshigamiTomoya KawaguchiYasutaka NakamuraHiroyasu Kaneda

Published in: International journal of clinical oncology (2024)

This study suggests the prognostic impact of concomitant BIO-three use in patients with advanced NSCLC on ICI treatment.

Keyphrases